Dr. Gary K. Schwartz, Professor of Medicine and Chief of the Division of Hematology and Oncology at NewYork-Presbyterian/Columbia University Medical Center was involved in and can speak to the recent phase II trial in which the data supported this accelerated approval.
The U.S. Food and Drug Administration granted accelerated approval to Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS), which are cancers that develop in muscles, fat, tendons or other soft tissues. Lartruvo is approved for use with the FDA-approved chemotherapy drug doxorubicin for the treatment of patients with STS who cannot be cured with radiation or surgery and who have a type of STS for which an anthracycline (chemotherapy) is an appropriate treatment.
“The improvement in overall survival observed with olaratumab for the treatment of patients with sarcoma represents a major new advance. Doxorubicin has been the standard of care for patients with metastatic sarcoma for decades. This is the first time that a drug, when added to doxorubicin, has been able to show results of meaningful improvement in survival in this disease. This accelerated approval of olaratumab by the FDA provides new hope to cancer patients with sarcoma.”
Dr. Schwartz is available for interviews.
To arrange an interview with Dr. Gary Schwartz, please call 212-821-0560 or email [email protected].
RSS